Table 1.
Description of trials by setting
| Number of patients (trials)* |
Disease-free or progression-free survival |
Overall survival |
|||
|---|---|---|---|---|---|
| Number of events | Median (range) survival | Number of deaths | Median (range) survival | ||
| Adjuvant therapy | |||||
| Chemotherapy vs no chemotherapy | 5379 (17) | 2525 | 6·4 years (0–16·7) | 2163 | 8·2 years (0–16·7) |
| Radiotherapy+chemotherapy vs radiotherapy alone | 2247 (7) | 1673 | 1·6 years (0–22·2) | 1566 | 2·5 years (0–22·2) |
| Locally advanced disease | |||||
| Radiotherapy+sequential chemotherapy vs radiotherapy alone | 1458 (8) | 1375 | 7·9 months (0–213·6) | 1333 | 11·7 months (0–213·6) |
| Radiotherapy+concurrent chemotherapy vs radiotherapy alone | 2552 (15) | 2391 | 8·1 months (0–189·6) | 2305 | 14·1 months (0–189·6) |
| Radiotherapy+sequential chemotherapy vs radiotherapy+concurrent chemotherapy | 1201 (6) | 1094 | 8·3 months (0–134·4) | 1065 | 14·6 months (0–134·4) |
| Modified radiotherapy vs standard radiotherapy | 2685 (12) | 2562 | 9·1 months (0–171·6) | 2471 | 15·0 months (0–171·6) |
*
In multiarm trials, control patients and treatment comparisons are counted twice; the total number of unique patients is 15 071 and of unique trials is 60.